Globally, the news is even more chilling. Cardiovascular disease kills upwards of 17 million people every year—one-third of all deaths worldwide. There has never been a more pressing need for cardiovascular research.
Whether it takes the form of cellular therapy, genomics, personalized medicine or treatment devices, the quest for translational research that serves as a link between biomedical research and clinical medicine has never been more focused or urgent.
The following studies and collaborations in cardiovascular disease are a sampling of many studies currently underway:
Michael S. Goligorsky, M.D., Ph.D., professor of medicine and of pharmacology and director of the Division of Nephrology, collaborate with Alvin Goodman, M.D., John McClung, M.D.’75, and Stephen Peterson, M.D., professors of medicine, to study vascular complications in cardiovascular diseases such as diabetes and hypertension.
William H. Frishman, M.D., chairman of the Department of Medicine and a clinical pharmacologist, has completed more than 300 research protocols funded by the NIH and private industry, and taken part in developing more than 100 cardiovascular drugs.
Thomas Hintze, Ph.D.’80, professor and chairman of the Department of Physiology, examines the pathophysiologic relevance of increasing and decreasing nitric acid production on the development of heart failure. He also has collaborations with with Julian Stewart, M.D., Ph.D., professor of pediatrics, to study the effect of nitric oxide on the autonomic nervous system, specifically in orthostatic intolerance, and with anesthesiologist Richard Levy, M.D., on cytochrome oxidase inhibition in the septic heart.
Michael S. Wolin, Ph.D., professor of physiology, studies how reactive oxygen and nitric oxide control signaling systems that affect contractile function in coronary arteries.